Sage Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Sage Therapeutics, Inc.

Sage Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States. Founded in 2010 as Sterogen Biopharma, Inc. and renamed Sage Therapeutics in 2011, the company is headquartered in Cambridge, Massachusetts. Sage focuses on central nervous system disorders, with a particular emphasis on neuroscience and mental health. Its strategy is built around discovering, developing, and where possible commercializing therapies that modulate key neurobiological pathways, especially the GABA and NMDA receptor systems. Sage’s business has historically been organized around a small but highly specialized portfolio of commercial and clinical-stage assets. Its most important commercial product is ZURZUVAE (zuranolone), which was approved by the FDA in August 2023 for the treatment of postpartum depression in adults. Sage began generating ZURZUVAE revenue in late 2023 through its U.S. collaboration with Biogen, making it the company’s primary monetization engine. The company also previously marketed ZULRESSO (brexanolone), but discontinued U.S. commercial availability at the end of 2024 and later withdrew the NDA in 2025, reflecting a sharper focus on the product with the strongest commercial potential. From a competitive standpoint, Sage is a niche CNS specialist rather than a diversified pharmaceutical player. Its main differentiator is scientific depth and the oral profile of ZURZUVAE in a historically underserved indication. At the same time, the company operates in a challenging competitive landscape, where larger pharmaceutical groups and emerging biotech peers are pursuing alternative approaches in psychiatry and neurology. Sage’s pipeline has also experienced several clinical setbacks, which has reduced visibility on its longer-term standalone growth profile. Geographically, Sage remains largely U.S.-centered in both operations and initial commercialization. Its international footprint is more reliant on collaborations and potential regulatory expansion than on a broad global infrastructure. Recent notable developments include the ramp-up of ZURZUVAE, the exit of ZULRESSO from the U.S. market, pipeline restructuring during 2025, and the announcement in June 2025 of an acquisition agreement by Supernus Pharmaceuticals. Taken together, these events place Sage Therapeutics in a transitional phase, with the Nasdaq-listed company evolving from a development-heavy CNS biotech toward a transaction-driven strategic outcome.